{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T11:48:00Z","timestamp":1711712880616},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,12,16]],"date-time":"2015-12-16T00:00:00Z","timestamp":1450224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,12,16]],"date-time":"2015-12-16T00:00:00Z","timestamp":1450224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Treatment of PBMC with the CD4-specific mAb BT-061 induces CD4 down-modulation of T cells. Here we report that addition of BT-061 to purified T cells did not confer this effect, whereas incubation of T cells in BT-061 coated wells restored CD4 down-modulation. These results implied that Fc\u03b3 receptor mediated cell-cell interactions played a role. In consistence with this hypothesis PBMC depleted of CD64<jats:sup>+<\/jats:sup> monocytes did not confer CD4 down-modulation of BT-061 decorated T cells. Strikingly, CD4 down-modulation was observed in BT-061 treated synovial fluid punctuated from patients\u2019 inflamed joints that comprised enhanced numbers of CD64<jats:sup>+<\/jats:sup> cells. In contrast, in a circulating whole blood system injection of BT-061 did not induce CD4 down-modulation, due to CD64 saturation by serum IgG. Similarly, tonsil derived mononuclear cells devoid of CD64<jats:sup>+<\/jats:sup> cells did not show CD4 down-modulation, whereas addition of blood derived monocytes restored the effect. Thus, the interaction of BT-061 decorated T cells with CD64<jats:sup>+<\/jats:sup> cells is needed for CD4 down-modulation, implying that in patients BT-061 would primarily induce CD4 down-modulation at inflammatory sites. These results highlight the need not only to examine the interaction of a given mAb with single Fc\u03b3R, but also the immunological environment that is appropriate to support such interactions.<\/jats:p>","DOI":"10.1038\/srep18308","type":"journal-article","created":{"date-parts":[[2015,12,16]],"date-time":"2015-12-16T11:22:45Z","timestamp":1450264965000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Antibody induced CD4 down-modulation of T cells is site-specifically mediated by CD64+ cells"],"prefix":"10.1038","volume":"5","author":[{"given":"Stephanie","family":"Vogel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Grabski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Buschj\u00e4ger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Klawonn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marius","family":"D\u00f6ring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junxi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingo","family":"Bechmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torsten","family":"Witte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Durisin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Burkhart","family":"Schraven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara M.","family":"Mangsbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kurt","family":"Sch\u00f6nfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niklas","family":"Czeloth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Kalinke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,12,16]]},"reference":[{"key":"BFsrep18308_CR1","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/312604a0","volume":"312","author":"MS Neuberger","year":"1984","unstructured":"Neuberger, M. S., Williams, G. T. & Fox, R. O. Recombinant antibodies possessing novel effector functions. Nature 312, 604\u2013608 (1984).","journal-title":"Nature"},{"key":"BFsrep18308_CR2","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.4049\/jimmunol.161.8.3862","volume":"161","author":"JD Isaacs","year":"1998","unstructured":"Isaacs, J. D., Greenwood, J. & Waldmann, H. Therapy with monoclonal antibodies. II. The contribution of Fc gamma receptor binding and the influence of C(H)1 and C(H)3 domains on in vivo effector function. J Immunol 161, 3862\u20133869 (1998).","journal-title":"J Immunol"},{"key":"BFsrep18308_CR3","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/nri2206","volume":"8","author":"F Nimmerjahn","year":"2008","unstructured":"Nimmerjahn, F. & Ravetch, J. V. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 8, 34\u201347 (2008).","journal-title":"Nat Rev Immunol"},{"key":"BFsrep18308_CR4","first-page":"674","volume":"5","author":"SQ Nagelkerke","year":"2014","unstructured":"Nagelkerke, S. Q. & Kuijpers, T. W. Immunomodulation by IVIg and the Role of Fc-Gamma Receptors: Classic Mechanisms of Action after all? Front Immunol 5, 674 (2014).","journal-title":"Front Immunol"},{"key":"BFsrep18308_CR5","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/jlb.61.1.6","volume":"61","author":"N Isakov","year":"1997","unstructured":"Isakov, N. Immunoreceptor tyrosine-based activation motif (ITAM), a unique module linking antigen and Fc receptors to their signaling cascades. J Leukoc Biol 61, 6\u201316 (1997).","journal-title":"J Leukoc Biol"},{"key":"BFsrep18308_CR6","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/jlb.63.5.521","volume":"63","author":"G Sanchez-Mejorada","year":"1998","unstructured":"Sanchez-Mejorada, G. & Rosales, C. Signal transduction by immunoglobulin Fc receptors. J Leukoc Biol 63, 521\u2013533 (1998).","journal-title":"J Leukoc Biol"},{"key":"BFsrep18308_CR7","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1056\/NEJMoa063842","volume":"355","author":"G Suntharalingam","year":"2006","unstructured":"Suntharalingam, G. et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355, 1018\u20131028 (2006).","journal-title":"N Engl J Med"},{"key":"BFsrep18308_CR8","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.4049\/jimmunol.1302461","volume":"192","author":"P Bartholomaeus","year":"2014","unstructured":"Bartholomaeus, P. et al. Cell contact-dependent priming and Fc interaction with CD32+ immune cells contribute to the TGN1412-triggered cytokine response. J Immunol 192, 2091\u20132098 (2014).","journal-title":"J Immunol"},{"key":"BFsrep18308_CR9","unstructured":"Hussain K. et al. Upregulation of Fc\u03b3RIIb on monocytes is necessary to promote the superagonist activity of TGN1412. Blood, blood-2014-2008-593061 (2014)."},{"key":"BFsrep18308_CR10","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1038\/nbt1252","volume":"24","author":"G Walsh","year":"2006","unstructured":"Walsh, G. & Jefferis, R. Post-translational modifications in the context of therapeutic proteins. Nat Biotechnol 24, 1241\u20131252 (2006).","journal-title":"Nat Biotechnol"},{"key":"BFsrep18308_CR11","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1084\/jem.20130573","volume":"210","author":"Y Bulliard","year":"2013","unstructured":"Bulliard, Y. et al. Activating Fc gamma receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med 210, 1685\u20131693 (2013).","journal-title":"J Exp Med"},{"key":"BFsrep18308_CR12","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.it.2014.05.002","volume":"35","author":"AJ Furness","year":"2014","unstructured":"Furness, A. J., Vargas, F. A., Peggs, K. S. & Quezada, S. A. Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies. Trends Immunol 35, 290\u2013298 (2014).","journal-title":"Trends Immunol"},{"key":"BFsrep18308_CR13","doi-asserted-by":"crossref","unstructured":"Deal watch: Boosting TRegs to target autoimmune disease. Nat Rev Drug Discov 10, 566 (2011).","DOI":"10.1038\/nrd3517"},{"key":"BFsrep18308_CR14","unstructured":"Germer, M., Osterroth, F., Aigner, S., Uherek, C., Kraus, E., Wartenberg-Demand, A., Wolf, D., Kaiser, S., Lindner, J., Bruecher, C., Daelken, B., BIOTEST, A. G., Germer, M., Osterroth, F., Aigner, S., Uherek, C., Kraus, E., Wartenberg-Demand, A., Wolf, D., Kaiser, S., Lindner, J., Bruecher, C. & Daelken, B. Agent for treating disease. United States Patent US 20,110,059,082. 2011 Mar 10."},{"key":"BFsrep18308_CR15","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1002\/eji.200636480","volume":"37","author":"C Becker","year":"2007","unstructured":"Becker, C., Kubach, J., Wijdenes, J., Knop, J. & Jonuleit, H. CD4-mediated functional activation of human CD4+CD25+ regulatory T cells. Eur J Immunol 37, 1217\u20131223 (2007).","journal-title":"Eur J Immunol"},{"key":"BFsrep18308_CR16","doi-asserted-by":"crossref","unstructured":"Helling, B. et al. A specific CD4 epitope bound by tregalizumab mediates activation of regulatory T cells by a unique signaling pathway. Immunol Cell Biol, (2014).","DOI":"10.1038\/icb.2014.102"},{"key":"BFsrep18308_CR17","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/0092-8674(92)90428-F","volume":"70","author":"DB Straus","year":"1992","unstructured":"Straus, D. B. & Weiss, A. Genetic evidence for the involvement of the lck tyrosine kinase in signal transduction through the T cell antigen receptor. Cell 70, 585\u2013593 (1992).","journal-title":"Cell"},{"key":"BFsrep18308_CR18","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.4049\/jimmunol.1003526","volume":"186","author":"CE van der Poel","year":"2011","unstructured":"van der Poel, C. E., Spaapen, R. M., van de Winkel, J. G. & Leusen, J. H. Functional characteristics of the high affinity IgG receptor, FcgammaRI. J Immunol 186, 2699\u20132704 (2011).","journal-title":"J Immunol"},{"key":"BFsrep18308_CR19","doi-asserted-by":"publisher","first-page":"6724","DOI":"10.4049\/jimmunol.0902374","volume":"183","author":"SM Mangsbo","year":"2009","unstructured":"Mangsbo, S. M. et al. Complement activation by CpG in a human whole blood loop system: mechanisms and immunomodulatory effects. J Immunol 183, 6724\u20136732 (2009).","journal-title":"J Immunol"},{"key":"BFsrep18308_CR20","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/BF01893018","volume":"7","author":"PJ Lachmann","year":"1984","unstructured":"Lachmann, P. J. & Hughes-Jones, N. C. Initiation of complement activation. Springer Semin Immunopathol 7, 143\u2013162 (1984).","journal-title":"Springer Semin Immunopathol"},{"key":"BFsrep18308_CR21","doi-asserted-by":"publisher","first-page":"181","DOI":"10.4161\/mabs.2.2.11158","volume":"2","author":"GL Moore","year":"2010","unstructured":"Moore, G. L., Chen, H., Karki, S. & Lazar, G. A. Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. mAbs 2, 181\u2013189 (2010).","journal-title":"mAbs"},{"key":"BFsrep18308_CR22","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/0090-1229(80)90185-3","volume":"16","author":"J Breard","year":"1980","unstructured":"Breard, J., Lazarus, H. & Schlossman, S. F. Generation and specificity of a heteroantiserum to human peripheral blood monocytes. Clin Immunol Immunopathol 16, 438\u2013446 (1980).","journal-title":"Clin Immunol Immunopathol"},{"key":"BFsrep18308_CR23","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1038\/nbt1207-1369","volume":"25","author":"JG Salfeld","year":"2007","unstructured":"Salfeld, J. G. Isotype selection in antibody engineering. Nat Biotechnol 25, 1369\u20131372 (2007).","journal-title":"Nat Biotechnol"},{"key":"BFsrep18308_CR24","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1074\/jbc.271.2.695","volume":"271","author":"JH Hanke","year":"1996","unstructured":"Hanke, J. H. et al. Discovery of a novel, potent and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation. J Biol Chem 271, 695\u2013701 (1996).","journal-title":"J Biol Chem"},{"key":"BFsrep18308_CR25","doi-asserted-by":"publisher","first-page":"222","DOI":"10.4049\/jimmunol.172.1.222","volume":"172","author":"G Criado","year":"2004","unstructured":"Criado, G. & Madrenas, J. Superantigen stimulation reveals the contribution of Lck to negative regulation of T cell activation. J Immunol 172, 222\u2013230 (2004).","journal-title":"J Immunol"},{"key":"BFsrep18308_CR26","doi-asserted-by":"publisher","first-page":"6772","DOI":"10.1182\/blood-2010-12-319780","volume":"118","author":"PS Romer","year":"2011","unstructured":"Romer, P. S. et al. Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412. Blood 118, 6772\u20136782 (2011).","journal-title":"Blood"},{"key":"BFsrep18308_CR27","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1136\/ard.2010.142091","volume":"70","author":"L Laurent","year":"2011","unstructured":"Laurent, L. et al. Fcgamma receptor profile of monocytes and macrophages from rheumatoid arthritis patients and their response to immune complexes formed with autoantibodies to citrullinated proteins. Ann Rheum Dis 70, 1052\u20131059 (2011).","journal-title":"Ann Rheum Dis"},{"key":"BFsrep18308_CR28","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1093\/rheumatology\/keh112","volume":"43","author":"AL Hepburn","year":"2004","unstructured":"Hepburn, A. L., Mason, J. C. & Davies, K. A. Expression of Fcgamma and complement receptors on peripheral blood monocytes in systemic lupus erythematosus and rheumatoid arthritis. Rheumatology (Oxford) 43, 547\u2013554 (2004).","journal-title":"Rheumatology (Oxford)"},{"key":"BFsrep18308_CR29","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1093\/rheumatology\/keg174","volume":"42","author":"S Wijngaarden","year":"2003","unstructured":"Wijngaarden, S., van Roon, J. A., Bijlsma, J. W., van de Winkel, J. G. & Lafeber, F. P. Fcgamma receptor expression levels on monocytes are elevated in rheumatoid arthritis patients with high erythrocyte sedimentation rate who do not use anti-rheumatic drugs. Rheumatology (Oxford) 42, 681\u2013688 (2003).","journal-title":"Rheumatology (Oxford)"},{"key":"BFsrep18308_CR30","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.4049\/jimmunol.143.7.2295","volume":"143","author":"AM Buckle","year":"1989","unstructured":"Buckle, A. M. & Hogg, N. The effect of IFN-gamma and colony-stimulating factors on the expression of neutrophil cell membrane receptors. J Immunol 143, 2295\u20132301 (1989).","journal-title":"J Immunol"},{"key":"BFsrep18308_CR31","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/art.1780140503","volume":"14","author":"I Kushner","year":"1971","unstructured":"Kushner, I. & Somerville, J. A. Permeability of human synovial membrane to plasma proteins. Relationship to molecular size and inflammation. Arthritis Rheum 14, 560\u2013570 (1971).","journal-title":"Arthritis Rheum"},{"key":"BFsrep18308_CR32","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/j.1365-2249.1995.tb03850.x","volume":"102","author":"J Highton","year":"1995","unstructured":"Highton, J., Carlisle B. & Palmer, D. G. Changes in the phenotype of monocytes\/macrophages and expression of cytokine mRNA in peripheral blood and synovial fluid of patients with rheumatoid arthritis. Clin Exp Immunol 102, 541\u2013546 (1995).","journal-title":"Clin Exp Immunol"},{"key":"BFsrep18308_CR33","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1046\/j.1365-2567.1997.00249.x","volume":"91","author":"JA Quayle","year":"1997","unstructured":"Quayle, J. A., Watson, F., Bucknall, R. C. & Edwards, S. W. Neutrophils from the synovial fluid of patients with rheumatoid arthritis express the high affinity immunoglobulin G receptor, Fc gamma RI (CD64): role of immune complexes and cytokines in induction of receptor expression. Immunology 91, 266\u2013273 (1997).","journal-title":"Immunology"},{"key":"BFsrep18308_CR34","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/BF00917426","volume":"11","author":"T Felzmann","year":"1991","unstructured":"Felzmann, T. et al. Analysis of function-associated receptor molecules on peripheral blood and synovial fluid granulocytes from patients with rheumatoid and reactive arthritis. J Clin Immunol 11, 205\u2013212 (1991).","journal-title":"J Clin Immunol"},{"key":"BFsrep18308_CR35","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.clim.2003.11.007","volume":"110","author":"MR Woolhiser","year":"2004","unstructured":"Woolhiser, M. R., Brockow, K. & Metcalfe, D. D. Activation of human mast cells by aggregated IgG through FcgammaRI: additive effects of C3a. Clin Immunol 110, 172\u2013180 (2004).","journal-title":"Clin Immunol"},{"key":"BFsrep18308_CR36","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1046\/j.1365-2249.2000.01171.x","volume":"119","author":"C Masson-Bessiere","year":"2000","unstructured":"Masson-Bessiere, C. et al. In the rheumatoid pannus, anti-filaggrin autoantibodies are produced by local plasma cells and constitute a higher proportion of IgG than in synovial fluid and serum. Clin Exp Immunol 119, 544\u2013552 (2000).","journal-title":"Clin Exp Immunol"},{"key":"BFsrep18308_CR37","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1084\/jem.20130579","volume":"210","author":"TR Simpson","year":"2013","unstructured":"Simpson, T. R. et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 210, 1695\u20131710 (2013).","journal-title":"J Exp Med"},{"key":"BFsrep18308_CR38","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1158\/2326-6066.CIR-13-0013","volume":"1","author":"MJ Selby","year":"2013","unstructured":"Selby, M. J. et al. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res 1, 32\u201342 (2013).","journal-title":"Cancer Immunol Res"},{"key":"BFsrep18308_CR39","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1007\/s12033-010-9340-z","volume":"47","author":"E Grabski","year":"2010","unstructured":"Grabski, E. et al. Comparative analysis of transduced primary human dendritic cells generated by the use of three different lentiviral vector systems. Mol Biotechnol 47, 262\u2013269 (2010).","journal-title":"Mol Biotechnol"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep18308.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep18308","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep18308.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T20:19:14Z","timestamp":1672949954000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep18308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,16]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,12,22]]}},"alternative-id":["BFsrep18308"],"URL":"https:\/\/doi.org\/10.1038\/srep18308","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,16]]},"assertion":[{"value":"12 August 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.C. is a former and K.S. a current employee of the Biotest AG, Dreieich. S.M. and E.F. are founders of Immuneed AB and S.M. is the CEO and a board member of Immuneed AB. The other authors have declared that no conflict of interest exists.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18308"}}